29th week of 2022 patent applcation highlights part 9 |
Patent application number | Title | Published |
20220226359 | ORALLY ADMINISTRABLE FORMULATIONS FOR THE CONTROLLED RELEASE OF A PHARMACOLOGICALLY ACTIVE AGENT - Drug tablets that include a controlled release layer of a moisture-sensitive active agent are prepared with a lipidic matrix forming excipient, a water-soluble, channel forming excipient and a filler, each being non-hygroscipic. The tablets are formed in a process where the components are blended in the absence of moisture and in particulate form. | 2022-07-21 |
20220226360 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF - The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus. | 2022-07-21 |
20220226361 | Compositions and Methods for Modulating MECP2 Expression - Disclosed herein are compounds and methods for decreasing MECP2 mRNA and protein expression. Such compounds and methods are useful to treat, prevent, or ameliorate MECP2 associated disorders and syndromes. Such MECP2 associated disorders include MECP2 duplication syndrome. | 2022-07-21 |
20220226362 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS - A compound comprising formula (I): | 2022-07-21 |
20220226363 | COMPOSITIONS AND METHODS FOR TREATING SARS-COV-2 INFECTION - The present disclosure provides small hairpin nucleic acid molecules capable of stimulating interferon production. The nucleic acid molecules of the present disclosure has a double-stranded section of less than 19 base pairs and at least one blunt end. In certain embodiments, the molecule comprises at least one 5′-triphosphate and/or at least one 5′-diphosphate. In certain embodiments, compounds and/or compositions of the disclosure are useful for treating, ameliorating, and/or preventing SARS-CoV-2 viral infection, and/or ameliorating, minimizing, reversing, and/or preventing persistent SARS-CoV-2 viral infection, and/or minimizing or preventing SARS-CoV-2 viral infection-derived mortality and/or lethality, in a subject. In certain embodiments, compounds and/or compositions of the disclosure are useful for treating, ameliorating, and/or preventing SARS-CoV-2 viral infection in a tumor-bearing subject. In certain embodiments, compounds and/or compositions of the disclosure are useful for treating, ameliorating, and/or preventing SARS-CoV-2 viral infection in an immune-compromised and/or immunodeficient subject. | 2022-07-21 |
20220226364 | THERAPEUTIC TARGETS FOR FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY - The disclosure relates to methods and compositions for regulating expression of DUX4. In some aspects, methods described by the disclosure are useful for treating a disease associated with aberrant DUX4 expression (e.g., facioscapulohumeral muscular dystrophy). | 2022-07-21 |
20220226365 | LIGHT-CURING COMPOSITIONS FOR TREATING ONYCHOMYCOSIS (FUNGAL NAIL INFECTION) - The present invention relates to photopolymerizable acrylate-based compositions for producing a light-curing lacquer for the therapy of onychomycosis or of a bacterial nail infection for a human or animal toenail or fingernail, the compositions being devoid of a classic antimycotic active ingredient. Various different acrylates can be used to produce the claimed compositions. | 2022-07-21 |
20220226366 | SUBSTITUTED PHENYL BORONIC ACID CONTAINING POLYMERS AND METHODS OF USE - The disclosure relates to cationic polymers functionalized with substituted phenylboronic acid groups and to methods of using the same to treat metabolic and gastrointestinal disorders. | 2022-07-21 |
20220226367 | THIOL AND DISULFIDE-CONTAINING AGENTS FOR INCREASING MEIBOMIAN GLAND LIPID SECRETION - Described herein are compositions and methods for the increasing the quantity of lipids secreted from meibomian glands. Such compositions and methods are useful for the treatment of meibomian gland dysfunction and disorders resulting therefrom. | 2022-07-21 |
20220226368 | ESSENTIALLY SODIUM-FREE EFFERVESCENT SOLID PHARMACEUTICAL COMPOSITIONS - Essentially sodium-free effervescent solid pharmaceutical compositions The present invention relates to an effervescent solid pharmaceutical composition, which is essentially free of sodium content, comprising: a therapeutically effective amount of an active pharmaceutical ingredient; one or more pharmaceutically acceptable alkaline earth metal carbonates or hydrogencarbonates in an amount from 1 to 31% by weight of the composition; and one or more pharmaceutically acceptable acids, pharmaceutically acceptable acid salts, or alternatively, a mixture thereof, in an amount from 2 to 62% by weight of the composition; together with one or more pharmaceutically acceptable excipients or carriers; wherein, the total content of the ion sodium in the effervescent solid pharmaceutical composition is equal to or lower than 1 mmol. It also relates to processes for its preparation and its use in therapy. | 2022-07-21 |
20220226369 | ETHANOL HARDENER AND USE THEREOF - Disclosed are an ethanol hardener and the use thereof. The ethanol hardener contains ethanol, a water-soluble iodine preparation and water, wherein the volume percent of the ethanol is 76-98%, and the mass-volume ratio of the iodine element in the water-soluble iodine preparation to the iodine containing composition is 23-139 g/L. The iodine containing composition can be autoradiographed when injected into blood vessels, and has a better embolization effect and stability. | 2022-07-21 |
20220226370 | GLYCEROL AND SODIUM PENTABORATE BASED FORMULATION PREVENTING POSTOPERATIVE ADHESIONS - A glycerol and sodium pentaborate based formulation developed for preventing postoperative adhesions occurring between manipulated tissues and organs is provided. An objective of the glycerol and sodium pentaborate based formulation is to provide a formulation comprising a mixture of glycerol, wherein the glycerol is one of the most abundant biomolecules in a human body, and sodium pentaborate, wherein the sodium pentaborate is known to have positive effects on a wound healing, with a purpose of preventing the postoperative adhesions. | 2022-07-21 |
20220226371 | Synthetic Cellular Membrane Chemical Ionophore Delivery System Comprising Hexa-Aqua Ligand Compositions - Synthetic ionophores for the active carry and transport of free ions across biological membranes in vivo, comprising coordination complexes of molecules with polarized hexa-aqua and/or tetra-aqua systems of free ionic metals and ionic salts as the ionophores, useful in transporting pharmaceutical, nutrient, and personal healthcare compounds. Also described are methods of their administration, methods of their synthesis and manufacture, and the ionophore products of such synthesis and manufacturing methods. | 2022-07-21 |
20220226372 | Use of metal ions to potentiate the therapeutic effects of arsenic - The present disclosure relates to a combination of an arsenic compound and a metal ion, for use as a medicament, wherein the metal ion increases the therapeutic effects of arsenic. | 2022-07-21 |
20220226373 | ADOPTIVE T CELL THERAPY 2 - The present disclosure relates to compositions comprising isolated T cells, with activity against a fungal antigen, a viral antigen or a tumour antigen, wherein the composition comprises a defined number or defined ratio of T cells. Described herein are compositions comprising at least two populations of T cells, the compositions being suitable for treating various diseases and disorders. | 2022-07-21 |
20220226374 | CD79B CHIMERIC ANTIGEN RECEPTORS - The invention provides improved compositions for adoptive cell therapies for cancers that express CD79B. The present invention relates to improved compositions and methods for treating cancer. More particularly, the invention relates to improved anti-CD79B chimeric antigen receptors (CARs), genetically modified immune effector cells, and use of these compositions to effectively treat CD79B expressing cancers. | 2022-07-21 |
20220226375 | ANTI-CD33 IMMUNE CELL CANCER THERAPY - Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer, such as CD33 | 2022-07-21 |
20220226376 | PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS - The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof. | 2022-07-21 |
20220226377 | TREATMENT OF DIABETES USING IMMUNE CELLS REPROGRAMMED EX VIVO BY REGENERATIVE CELLS - Disclosed are methods of ameliorating, inhibition, and/or reversing diabetes utilizing immune cells that have been reprogrammed ex vivo by contact with regenerative cells. In one embodiment said reprogrammed immune cells comprise peripheral blood mononuclear cells obtained from the patient in need of treatment wherein said cells are endowed with properties of immune modulation, and/or suppression of inflammation, and/or restoration of insulin sensitivity, and/or pancreatic regeneration. In one embodiment regenerative cells used for reprogramming are mesenchymal stem cells. In one particular embodiment said cells are umbilical cord derived mesenchymal stem cells. Culture of peripheral blood mononuclear cells together with said regenerative cells is performed in the presence of interleukin-2 and/or an mTOR inhibitor. In one embodiment said mTOR inhibitor comprises rapamycin and/or a derivative thereof. | 2022-07-21 |
20220226378 | METHOD FOR TREATING CANCER - Provided herein are methods for treating or ameliorating malignant diseases, such as cancers. Also provided herein are methods of increasing the immunity of an immune cell toward malignant cells. | 2022-07-21 |
20220226379 | DNMT3A KNOCK-OUT STAT5 ACTIVATED GENETICALLY ENGINEERED T-CELLS - The application provides modified immune effector cells wherein the DNA (cytosine-5)-methyltransferase 3A (DNMT3A)-mediated de novo DNA methylation of the cell genome is inhibited, and STAT5 signaling pathway is activated. The application also provides related pharmaceutical compositions and the methods for generating such modified immune effector cells. The application further provides uses of such modified immune effector cells for treating diseases such as cancers, infectious diseases and autoimmune diseases. | 2022-07-21 |
20220226380 | GENE KNOCK-OUTS TO IMPROVE T CELL FUNCTION - The present application provides methods of enhancing T cell function (e.g., expansion, persistence and/or effector functions), particularly by genetic modification of the Regnase-1, Batf, and additional genes (alone or in combination). The application also provides modified T cells manufactured using the methods provided by this invention and related pharmaceutical compositions. The application further provides methods of using the modified T cells for treating a disease (e.g., a cancer or an infectious disease). | 2022-07-21 |
20220226381 | Coordinating Gene Expression Using RNA Destabilizing Elements - Control Devices are disclosed including RNA destabilizing elements (RDE), and RNA control devices, combined with transgenes, including Chimeric Antigen Receptors (CARs) in eukaryotic cells. RDEs can be combined with RNA control devices to make RDEs that include ligand mediated control. These smart RDEs and other RDEs can be used to optimize expression of transgenes, e.g., CARs, in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered at desired times from the eukaryotic cell. | 2022-07-21 |
20220226382 | Nutritional Composition - An object of the present invention is to provide a technique for preventing infection of pathogenic viruses, which cause infectious diseases in animals or humans. A nutritional composition containing lactoferrin and/or lactoferrin hydrolysate, and human milk oligosaccharide is provided. One or more human milk oligosaccharides are preferably 2′-fucosyllactose, 3-fucosyllactose, 3′-sialyllactose, and 6′-sialyllactose. The nutritional compositions of the present invention can be used for preventing infection, especially for preventing viral infection. | 2022-07-21 |
20220226383 | METHOD OF PRESERVING CELLS FOR THERAPEUTIC USE - Disclosed is a composition including, in a physiologically acceptable medium: a) at least one saccharide; b) at least one vitamin; c) at least one amino acid; d) at least one antioxidant; and e) cells for therapeutic use. The composition has a pH between 7.0 and 8.5, inclusive, and preferably between 7.0 and 8.3. Also disclosed is a method of preserving a sample of cells for therapeutic use, including at least one step of mixing the sample of cells for therapeutic use with the ingredients a) to d) above and a physiologically acceptable medium, the composition that is obtained having a pH between 7.0 and 8.5, inclusive, and preferably between 7.0 and 8.3. | 2022-07-21 |
20220226384 | EXTRACELLULAR VESICLE COMPOSITIONS AND METHODS OF USE THEREOF - Compositions and methods for promoting generation or regeneration of the lymphatic system in a subject are provided. Compositions and methods for the treatment of lymphedema are also provided. The composition can include extracellular vesicles and a pharmaceutically acceptable carrier, and is typically cell-free. In some embodiments, the extracellular vesicles are formed by a method including culturing MSCs to produce media conditioned with the extracellular vesicles, and optionally, but preferably separating the extracellular vesicles from the media conditioned by the MSCs. In some embodiments, the extracellular vesicles include or consist of exosomes, microvesicles or a combination thereof, and they may have a size of between about 20 nm and about 500 nm. In some embodiments, extracellular vesicles include CD9, CD63, or a combination thereof and/or one or more of miR-199a-3p, miR-145-5p, miR-143-3p, miR-377-3p, miR-100-3p, miR-29a-3p, miR-495-3p, miR-29c-3p, miR-658, miR-493-3p, miR-184, and miR-27a-3p. | 2022-07-21 |
20220226385 | PHARMACEUTICAL COMPOSITION COMPRISING PERIODONTAL TISSUE-DERIVED PLURIPOTENT STEM CELLS FOR PREVENTION OR TREATMENT OF MALE INFERTILITY - The present invention relates to a pharmaceutical composition including vitrified periodontal tissue-derived mesenchymal stem cells for prevention or treatment of male infertility. The pharmaceutical composition for prevention or treatment of male infertility according to the present invention recovers sex hormone levels in seminiferous tubules of atrophic testes and blood to normal levels through improvement in the activity of lipid metabolism enzymes in the liver, thereby exhibiting remarkable prophylactic and therapeutic effects on male infertility. In addition, the periodontal tissue-derived mesenchymal stem cells which are an active ingredient in the present invention can be obtained in the most non-invasive manner and as such, are expected to be advantageously used as a cell therapy product for male infertility. | 2022-07-21 |
20220226386 | FUNCTIONAL RECOVERY FROM CEREBRAL INFARCTION - The present disclosure provides methods of treating a subject who has suffered a cerebral infarction, the method comprising administering systemically to the subject a population of cells enriched for mesenchymal lineage precursor or stem cells (MLPSCs) such as STRO-1 | 2022-07-21 |
20220226387 | PHARMACEUTICAL COMPOSITION FOR PROMOTING OSTEOGENESIS, COMPRISING OSTEOBLAST-DERIVED MITOCHONDRIA - The present invention relates to a pharmaceutical composition for promoting osteogenesis and a pharmaceutical composition for treating bone diseases, the compositions comprising osteoblast-derived mitochondria as an active ingredient. | 2022-07-21 |
20220226388 | CELL CULTURE FOR TREATING INFLAMMATORY DISEASE - Systems and methods of the present disclosure include a cell culture, a method for producing the cell culture, a kit for producing the cell culture, a method for treating inflammatory disease using the cell culture, and the like, for treating inflammatory disease. The cell culture containing cells can be derived from skeletal muscle. | 2022-07-21 |
20220226389 | EXTRACELLULAR VESICLES FROM HUMAN LIVER STEM CELLS (HLSC-EVS) FOR REDUCING CELLULAR SENESCENCE - There is disclosed a preparation of extracellular vesicles derived from human liver stem cells, preferably from a non-oval human progenitor cell line that expresses hepatic cell markers, which is capable of reducing the senescence of a population of senescent cells, as measured in a SA-β-galactosidase-based cellular senescence assay. Also disclosed are therapeutic applications of the preparation of extracellular vesicles derived from human liver stem cells according to the invention. Therapeutic applications include the reduction of cellular senescence, e.g. in an vitro or ex vivo method, as well as the therapeutic treatment of diseases and conditions known to be related to ageing and cellular senescence, such as for example atherosclerosis, diabetes mellitus type 2, asthenia, and others. | 2022-07-21 |
20220226390 | CLINICAL-GRADE AUTOLOGOUS BRONCHIAL BASAL CELL, DELIVERABLE FORMULATION, AND PREPARATION PROCESS - Provided are a clinical-grade autologous bronchial basal cell, a deliverable formulation thereof, and a preparation process. The preparation process comprises the following steps: acquiring and digesting an in vitro active bronchoscopic brushed-off biopsy tissue, and collecting cells after digestion is terminated; plating the digested cells on a culture plate pre-coated with feeder layer cells, collecting the cultured cells to perform amplification culture on a culture plate pre-coated with feeder layer cells, and when the cells grow to cover 50%-90% of the surface area of the culture plate, performing cell passage operation; and when passaged culture cells grow to cover 85%-95% of the surface area of a culture dish, digesting and collecting adhered cells, and washing. The clinical-grade bronchial basal cell prepared by this method can differentiate stably after the cells reach the lesion and significantly achieve the damaged lung tissue regeneration. | 2022-07-21 |
20220226391 | COMPOSITIONS AND METHODS FOR THYMIC REGENERATION AND T-CELL RECONSTITUTION - The present invention provides non-thymic endothelial cells (ntECs) engineered to express adenovirus E4ORF1 and/or BMP4, and compositions comprising such engineered ntECs. The present invention also provides methods of using such ntECs in therapy, for example to enhance thymic regeneration (including T cell reconstitution) in subjects in need thereof. Such subjects include those that have a damaged thymus, defective thymic function, insufficient T-cell output, and/or that are immunocompromised—for example as a result of ageing, infection (e.g. with HIV), treatment with radiation therapy, treatment with chemotherapy, or myeloablative conditioning in preparation for an organ/tissue transplant. | 2022-07-21 |
20220226392 | COMPOSITIONS AND PROCESS FOR INTEGRATING CELLS INTO EPITHELIUM - The invention provides a combination of compositions comprising in a first composition | 2022-07-21 |
20220226393 | USE OF PARASITES AND EXTRACELLULAR VESICLES OBTAINED FROM PARASITES IN CANCER TREATMENT - Use of parasites and extracellular vesicles obtained from the parasites for a cancer treatment is provided. The use of parasites and extracellular vesicles obtained from parasites is for using in a treatment of a cancer, and loading an active substance on exosomes by using a drug loading capacity of exosomes, and thus, by carrying a specific drug directly to target cancer cells without causing any side effect on healthy cells and to enhance a bioavailability of the specific drug, achieving a desired effect in a tumor specific target region. Particularly | 2022-07-21 |
20220226394 | ALGORIPHAGUS SP, BOSEA SP, BREVUNDIMONAS SP, DESULFOVIBRIO SP, MICROBACTERIUM SP, SPHINGOMONAS SP, AND VARIOVORAX SP FOR USE IN DISEASE PREVENTION AND TREATMENT - A treatment compound and its use in the prevention and treatment diseases are disclosed. The compound comprises one or more materials selected from an algal biomass/supernatant (including both algae and bacteria), a bacterial biomass, and isolated and purified compound(s) as well as specific active sites or structures on those compounds. The treatment compound and the use of such a compound such as that derived from a bacterium that appears to selectively alter one or more TLR pathways in the prevention and treatment of disease in both animals and humans. The bacteria are selected from the group consisting of | 2022-07-21 |
20220226395 | BACTERIA ENGINEERED TO TREAT METABOLIC DISEASES - Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of attenuating metabolic diseases are disclosed. | 2022-07-21 |
20220226396 | ANTIBACTERIAL AGENTS & METHODS - The invention relates to means for carrying out conjugation between bacteria, and in particular the invention relates to carrier bacteria comprising antimicrobial agents and methods of use. The carrier bacteria are capable of conjugative transfer of DNA encoding the agent to a target cells. The invention further relates to growth or feed conversion ratio promotion in animals. The invention further relates to killing | 2022-07-21 |
20220226397 | SYNERGISTIC COMBINATIONS OF ARGININE-PRODUCING BACTERIA AND/OR AMMONIA-CONSUMING BACTERIA AND CHECKPOINT INHIBITORS AND METHODS OF USE THEREOF - Disclosed herein are synergistic compositions and methods using arginine-producing bacteria and/or ammonia-consuming bacteria in combination with a checkpoint inhibitor for use in treating cancer. | 2022-07-21 |
20220226398 | ALGORIPHAGUS SP, BOSEA SP, BREVUNDIMONAS SP, DESULFOVIBRIO SP, MICROBACTERIUM SP, SPHINGOMONAS SP, AND VARIOVORAX SP FOR USE IN DISEASE PREVENTION AND TREATMENT - A treatment compound and its use in the prevention and treatment diseases are disclosed. The compound comprises one or more materials selected from an algal biomass/supernatant (including both algae and bacteria), a bacterial biomass, and isolated and purified compound(s) as well as specific active sites or structures on those compounds. The bacteria are selected from the group consisting of | 2022-07-21 |
20220226399 | METHOD FOR GUT MUCOSA PREPARATION TO ENHANCE MICROBIAL ENGRAFTMENT - In alternative embodiments, provided are products of manufacture for microbiome transplantation and engraftment, including fecal microbiota transplantation (FMT) delivery devices, and methods for using them, including methods for replacing an individual's gastrointestinal (GI), e.g., colonic, microbiome, and methods for the treatment, amelioration or prevention of an in situ microbiome space, or a gastrointestinal (GI) disease, infection or condition or a disease or condition caused by, initiated by or exacerbated by a pathological microbiome, e.g., pathological GI or colonic microbiome. In particular a method for microbiome transplantation and engraftment in an individual in need thereof, the method comprising: removing of some or all colonic fecal material from the colon of the individual in need thereof by washing out colonic fecal material from the colon, wherein said washing out comprises administering a formulation comprising a biofilm dissolving or disrupting agent to the colon, and administering a FMT material, liquid, formulation or solution, or a normal microbiome, to the individual in need thereof. | 2022-07-21 |
20220226400 | Detection, Treatment, and Monitoring of Microbiome-Mediated Cholesterol Homeostasis - Elucidating the relationship between specific intestinal bacteria, dietary intake, and the health of the host remains a primary goal for gut microbiome research. Prebiotics, substrates that are selectively used by microorganisms to promote the health of the host, present an appealing therapeutic option. We performed correlation analysis to identify relationships between health parameters and populations of gut bacteria in participants from a randomized, placebo-controlled clinical trial testing the effects of a prebiotic digestion resistant potato starch (DRS; MSPrebiotic®). This study focused on the abundance of | 2022-07-21 |
20220226401 | DENGUE VACCINE UNIT DOSE AND ADMINISTRATION THEREOF - The invention relates to a unit dose of a dengue vaccine composition and methods and uses for preventing dengue disease and methods for stimulating an immune response to all four dengue virus serotypes in a subject or subject population. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection. | 2022-07-21 |
20220226402 | METHODS AND COMPOSITIONS COMPRISING ENHANCED TARGETED IMMUNE GENE THERAPY FOR THE TREATMENT OF CANCER - Provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of an adenoviral vector with a genetically modified fiber incorporating a Lyp-1 peptide motif and at least one CD122/CD132 agonist and/or an immune checkpoint inhibitor. | 2022-07-21 |
20220226403 | METHODS OF IMPROVING REPRODUCTIVE AND RESPIRATORY HEALTH - The present invention encompasses methods of improving reproductive and respiratory health. | 2022-07-21 |
20220226404 | MEDICAL COMPOSITIONS WITH OMEGA-3 CONTAINING EXCIPIENTS - A composition comprising a concentration of total lipids, wherein at least 20% of the total lipids concentration by weight % comprises a polar lipids fraction, with greater than about 30% by weight % of the polar lipids fraction comprising glycolipids, and wherein the composition comprises no greater than 4% of its weight % as chlorophyll concentration, and formulations and medical compositions including the lipids-containing composition. | 2022-07-21 |
20220226405 | METHODS AND COMPOSITIONS COMPRISING PSYCHOACTIVE COMPOUNDS FROM PSYCHOACTIVE ORGANISMS - This invention relates to the extraction of psychoactive compounds from organisms for use in medicine. Extraction is carried out with a strong acid or strong base to either promote or inhibit dephosphorylation. The extract in the slurry form is standardized with added excipient so that when it is dried the powdered composition has a specified total psychoactive alkaloid concentration, with a known ratio of phosphorylated to dephosphorylated psychoactive alkaloids. | 2022-07-21 |
20220226406 | COMPOSITION CONTAINING EXTRACT OF CANNABIS SATIVA FOR PREVENTING OR TREATING METABOLIC SYNDROME-RELATED DISEASE - The present disclosure relate to a composition for preventing and treating metabolic disease containing a | 2022-07-21 |
20220226407 | PHARMACEUTICAL COMPOSITION COMPRISING THE EXTRACT OF CANNABIS SATIVA AS AN EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING OF OBESITY - The present disclosure relates to a composition for preventing and treating obesity containing a | 2022-07-21 |
20220226408 | INGESTIBLE FILMS HAVING SUBSTANCES FROM HEMP OR CANNABIS - Films that are mucosally dissolvable, and containing a matrix and one or more active agents from hemp or cannabis within the matrix, are provided. The disclosure also provides methods for preparing such a film for pharmaceutical and nutraceutical applications. | 2022-07-21 |
20220226409 | COMPOSITION FOR STIMULATING OF MYOGENESIS AND PREVENTION OF MUSCLE DAMAGE CONTAINING GINSENG EXTRACT - The present disclosure relates to a composition for stimulating of myogenesis and prevention of muscle damage, comprising a ginseng extract. More specifically, the present disclosure provides a composition for stimulating of myogenesis and prevention of muscle damage, comprising non-saponin components of ginseng, which may rapidly recover the damaged muscles by stimulating myogenesis and increasing an expression of proteins related with a muscle control. | 2022-07-21 |
20220226410 | CACTI AND CACTI PARTS FOR COSMETIC TREATMENT OF SKIN AND BALDNESS AND HAIR REGENERATION AND REGROWTH - The invention pertains to cosmetic preparations based on the biome of cacti plants, namely the body of cacti plants, cacti plants fruits and derivatives of cacti plants. Such preparations are suitable for topical or dermatological treatment of skin, scalp skin, hair loss, baldness and hair regeneration. The active ingredient of such composition or preparation for such cosmetic topical application or personal care treatment includes selected relative amounts of extracts and parts of | 2022-07-21 |
20220226411 | PREPARATIONS AND COMPOSITIONS COMPRISING CACTI AND CACTI PARTS FOR ANTIMICROBIAL, ANTIVIRAL AND ANTIFUNGAL ACTIVITY - The invention provides a pharmaceutical composition for treating disorders, diseases and conditions selected from viral diseases, diabetes, lower blood sugar levels in people with type 2 diabetes, high cholesterol, obesity, enlarged prostate and hangovers and viral, bacterial and oxidation related diseases and disorders. The ingredients of the pharmaceutical composition are selected relative amounts of parts and/or extracts of | 2022-07-21 |
20220226412 | NUTRITION BLEND FOR HEALTH BENEFITS IN ANIMALS - Methods and compositions for providing a health benefit to an animal using a nutrient blend. In one embodiment, the method can comprise orally administering a composition comprising at least four of the nutrients selected from the group of walnut, maitake mushroom extract, EGCG, turmeric root powder, lycopene, taurine, EPA, and DHA to the animal. | 2022-07-21 |
20220226413 | TRADITIONAL CHINESE MEDICINE COMPOSITION WITH IMPROVING COGNITION EFFECT, PREPARATION METHOD THEREOF AND TRADITIONAL CHINESE MEDICINE PREPARATION - The present disclosure relates to the technical field of traditional Chinese medicine, and more specifically, to a traditional Chinese medicine composition with improving cognition effect, its preparation method and a traditional Chinese medicine preparation. In parts by weight, the traditional Chinese medicine composition is made from 1-20 parts of | 2022-07-21 |
20220226414 | COVID-19 Treatment - The disease due to infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) referred to as Coronavirus disease 2019 (COVID-19) can be treated by using a product in the form of Semen Nigella Sativa Oil (oil from Habbatus sauda seed or black cumin seed) as an ingredient or drug for COVID-19 treatment that is taken orally. The consumption is carried out daily, three times a day, with each consumption the composition of the oil content of the black cumin seeds is composed of about 450 mg, according to weight, until recovered from COVID-19. | 2022-07-21 |
20220226415 | SUPPLEMENT, DELIVERY METHOD AND DEVICE FOR SAID SUPPLEMENT - A supplement formulation including a combination of vitamins, minerals, amino acids, and stimulants, and a delivery method and device for said supplement formulation. Caffeine is present in the supplement formulation in an amount of about 40-60 mg/ml, of which about 15-30 mg/ml is caffeine from coffee beans and about 15-30 mg/ml is caffeine from green tea extract. About 5-20 mg/ml caffeine from guarana seed extract may also be present. Such a delivery device provides the supplement to a mouth/throat area of a user where it is readily absorbed in the mouth/throat area of the user or ingested by the user. | 2022-07-21 |
20220226416 | OXYGENATED CANNABIS SKIN THERAPY COMPOSITIONS AND METHODS FOR PRODUCING THE COMPOSITIONS - Provided are oxygenated cannabis skin therapy compositions, and methods for preparing the compositions by ozonating coconut oil, extracting medicinal/recreational cannabis into coconut oil to yield a cannabis infused coconut oil, and combining the ozonated coconut oil with the cannabis infused coconut oil to yield the skin therapy compositions. | 2022-07-21 |
20220226417 | COMPOSITIONS INCLUDING PIPERONYL BUTOXIDE AND PYRETHRUM EXTRACT - In an embodiment, the present disclosure pertains to a lice-treating gel composition. In some embodiments, the composition includes piperonyl butoxide with a concentration from about 0.5 to 5 wt/wt %, pyrethrum with a concentration from about 0.1 to 1 wt/wt %, citronella with a concentration from about 0.1 to 1 wt/wt %, lemongrass oil with a concentration from about 0.01 to 0.5 wt/wt %, and tea tree oil with a concentration from about 0.01 to 0.5 wt/wt %. In an additional embodiment, the present disclosure pertains to a lice-treating gel composition including piperonyl butoxide with a concentration of about 3.889 wt/wt %, pyrethrins with a concentration of about 0.6 wt/wt %, citronella with a concentration of about 0.66 wt/wt %, lemongrass oil with a concentration of about 0.14 wt/wt %, and tea tree oil with a concentration of about 0.1 wt/wt %. | 2022-07-21 |
20220226418 | FINE BAMBOO POWDER AND PREPARATION METHOD THEREFOR AND USE THEREOF - A MATZHU is prepared by using leaves of Gramineae (Graminae) and Bambusoideae plant as raw materials, and has a stable emerald color, and has an average powder particle size of 800 to 10,000 meshes, and has a total amount of dietary fiber of ≥60%, a content of lignin of ≥20% and a content of minerals of ≥7%, and comprises at least three or more bamboo leaf characteristic components, such as orientin, isoorientin, vitexin, isovitexin, adenosine, δ-hydroxylysine and p-coumaric acid. The method for the MATZHU preparation comprises, in turn, performing blanching and color protection, drying and superfine grinding the raw materials. By utilizing the thermal stability and the light stability of the MATZHU, the MATZHU may be used as a raw food material, a functional ingredient, or a dietary supplement. | 2022-07-21 |
20220226419 | A PHARMACEUTICAL KIT FOR ALLEVIATING ADVERSE EFFECTS OF CHEMOTHERAPY - The present disclosure relates to a pharmaceutical kit for alleviating adverse effects of chemotherapy, reducing oxidative stress, improving immunomodulatory response and quality of life. The pharmaceutical kit comprises Suvarna bhasmadi Vati (SBD), Mouktikyukta Kamdudha Vati (MKD), Padmakadi Ghrut (PDG), and Ananta vati. The pharmaceutical kit of the present disclosure can be used for alleviating adverse effects of chemotherapy such as nausea, vomiting, anorexia, fever, taste alteration, fatigue, dyspepsia, and mucositis. It can also improve immune status and reduce oxidative stress leading to betterment of the quality of life of the patients treated with chemotherapy. The pharmaceutical kit of the present disclosure may be beneficial in cancers and diseases for which chemotherapy is a treatment of choice. | 2022-07-21 |
20220226420 | HEALTH PRODUCTS FROM GARLIC GREEN TOPS - A process for harvesting and preparing green garlic leaves and shoots (green tops) for the production of ajoene and garlic oil for use in medicine and foods, the method including the steps of garlic green top separation from bulbs during harvesting, collecting, shredding, blending, extracting or converting and then adding to fortify butter, margarine and medicinal capsules and edible oils. | 2022-07-21 |
20220226421 | COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING METABOLIC SYNDROME ACCOMPANIED BY OBESITY AND/OR DIABETES, CONTAINING, AS ACTIVE INGREDIENT, COMPLEX (IB COMPLEX) OF INDIAN GOOSEBERRY EXTRACT AND SPROUT BARLEY EXTRACT - The present invention relates to a composition for prevention, improvement or treatment of metabolic syndrome comprising a complex of Indian gooseberry (amla) extract and barley sprout extract as an active ingredient. Specifically, the complex of Indian gooseberry extract and barley sprout extract reduces a body weight, blood sugar, insulin in blood and glycated hemoglobin in blood, and thereby it shows a synergistic effect in improvement of obesity or diabetes, and therefore it can be used as a pharmaceutical composition or health functional food for prevention or treatment of metabolic syndrome such as obesity and diabetes. | 2022-07-21 |
20220226422 | METHOD OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST - The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect. The present disclosure also provides for methods for treating prostate cancer in a patient with a history of at least one cardiovascular event, wherein administration of degarelix to the subject decreases the likelihood of developing or experiencing an additional cardiovascular event compared to treatment with a gonadotrophin releasing hormone (GnRH) agonist. | 2022-07-21 |
20220226423 | STABLE PHARMACEUTICAL COMPOSITION OF VASOPRESSIN - The present invention relates to a stable pharmaceutical composition comprising vasopressin or pharmaceutically acceptable salts thereof. The present invention further provides a method of increasing blood pressure in adults with vasodilatory shock by administering said pharmaceutical composition of vasopressin or pharmaceutically acceptable salts thereof. | 2022-07-21 |
20220226424 | METHOD OF ENHANCING THE THERAPEUTIC EFFICACY OF FEXAPOTIDE TRIFLUTATE IN TREATING LUTS - Disclosed are methods of enhancing the therapeutic efficacy of Fexapotide Triflutate (TF) in treating LUTS, both irritative and obstructive, that include administering a composition comprising FT at least twice over a period spanning more than one year. The methods are capable of providing an enhanced therapeutic effect in treating nocturia, and in improving urinary flow, when compared to the therapeutic effect achieved by administration of the same or twice the total amount of FT administered. | 2022-07-21 |
20220226425 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS - The disclosure is related to a method of treating a disorder, such as obesity or a condition associated with obesity, such as hyperphagia, in a subject using a melanocortin-4 receptor (MC4R) agonist. | 2022-07-21 |
20220226426 | OPHTHALMIC COMPOSITION FOR THE TREATMENT OF OCULAR ALLERGY - The invention provides ophthalmic composition comprising cyclosporine and a semifluorinated alkane for use in the treatment of ocular allergy and any symptoms associated thereto. | 2022-07-21 |
20220226427 | OPHTHALMIC COMPOSITION FOR TREATMENT OF DRY EYE DISEASE - The invention provides ophthalmic compositions comprising about 0.1% (w/v) cyclosporine dissolved in 1-(perfluorobutyl)pentane for use in the topical treatment of dry eye disease and provides for treatment methods thereof. The invention further provides kits comprising such compositions. | 2022-07-21 |
20220226428 | PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS - By employing a pharmacodynamic dosing regimen, the effectiveness of a protocol for treatment of a proteinuric kidney disease with voclosporin can be maximized while minimizing undesirable side effects. | 2022-07-21 |
20220226429 | NOVEL ENTERIC COMBINATION THERAPY - There is disclosed herein a composition for treating gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux esophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinson's disease, MS, Alzheimer's Disease, Motor Neuron Disease or autism, the composition comprising: (i) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (ii) at least one anti-clostridial agent selected from the above combined with an opioid blocking agent. There is also disclosed herein a method of treating various gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinson's disease, MS, Alzheimer's Disease, Motor Neuron Disease or autism, the method comprising administering orally, via enema or by suppository: (i) a composition of the invention; (ii) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (iii) at least one anti-clostridial agent selected from the above and an opioid blocking agent to a patient in need of such treatment. | 2022-07-21 |
20220226430 | PROTEIN INHIBITORS OF CLOSTRIDIUM DIFFICILE TOXIN B - In an embodiment, the present disclosure pertains to a method of treating or preventing | 2022-07-21 |
20220226431 | ANTI-ANGIOGENIC TREATMENT USING VLO4 WITH A BLOCKING PEPTIDE - The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an α5β1 antagonist with an α2β1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of VLO4 and VP12 (ECL12). | 2022-07-21 |
20220226432 | DEFERRED TREATMENT OF NERVE INJURIES - Deferred treatment of nerve injuries is provided. Accordingly, there is provided a method of deferred treatment of a nerve injury in a subject in need thereof, the method comprising implanting at least 1 week following onset or diagnosis of the nerve injury in the subject a composition comprising a hyaluronic acid, a laminin polypeptide and an antioxidant at or near the nerve injury of the subject. | 2022-07-21 |
20220226433 | Method to Identify Responders to Osteoarthritis Therapeutics - A diagnostic and a method of treatment are disclosed whereby the diagnostic identifies patients more likely to respond to a therapeutic intervention thereby improving clinical benefits including improved joint function, reduced pain, and other clinical symptoms. | 2022-07-21 |
20220226434 | METHODS OF TREATING HYPERLIPIDEMIA CONDITIONS WITH NETRIN-1 COMPOUNDS - Disclosed herein are netrin 1 compounds and compositions thereof and methods of using thereof to treat, inhibit, or reduce conditions associated with or resulting from hyperlipidemia. | 2022-07-21 |
20220226435 | Ciliary Neurotrophic Factor Receptor Ligands and Methods of Using the Same - Provided are ciliary neurotrophic factor receptor (CNTFR) ligands. In certain aspects, a CNTFR ligand of the present disclosure exhibits increased affinity for CNTFR relative to the corresponding wild-type CNTFR ligand. In certain aspects, a CNTFR ligand of the present disclosure results in reduced binding affinity of glycoprotein 130 (gp130), leukemia inhibitory factor receptor (LIFR), or both, for a complex including the CNTFR ligand and CNTFR, relative to the binding affinity for a complex including the corresponding wild-type CNTFR ligand and CNTFR. In certain aspects, a CNTFR ligand of the present disclosure has both of the aforementioned properties. Also provided are pharmaceutical compositions including the CNTFR ligands, as well as methods of using the CNTFR ligands. | 2022-07-21 |
20220226436 | MUCOADHESIVE MICROGEL COMPOSITIONS AND METHODS FOR USING THE SAME - Mucoadhesive microgel compositions, which include an active agent (such as HB-EGF), are provided. Aspects of the invention include a microgel comprising a crosslinked poly(ethylene glycol) methyl ether methacrylate polymer comprising a mucoadhesive functionality. Also provided are methods of making and using the mucoadhesive microgel compositions, e.g., in therapeutic applications. In one embodiment, HB-EGF loaded mucoadhesive microgel compositions are provided, e.g., for prevention or treatment of mucositis conditions, such as therapy induced oral mucositis conditions. | 2022-07-21 |
20220226437 | Fibroblast growth factor 2 (FGF2) for Treatment of Human Sensorineural Hearing Loss - Methods of using Fibroblast growth factor 2 (FGF2) to treat subjects with hearing loss associated with impaired word recognition. | 2022-07-21 |
20220226438 | COMPOSITIONS FOR SKIN AND WOUNDS AND METHODS OF USE THEREOF - This disclosure relates to mRNA therapy for (i) the promotion and/or improvement of wound healing, (ii) the prevention and/or reduction of scar formation at a wound, (iii) the reduction of the visibility of a scar, and/or (iv) the treatment of epidermolysis bullosa. mRNAs for use in the invention, when intradermally (e.g., using microneedles) or topically administered in vivo, encode a wound healing polypeptide (e.g., a growth factor, a cytokine, a chemokine, a protease inhibitor, or a collagen). | 2022-07-21 |
20220226439 | METHODS OF REDUCING SIDE EFFECTS OF ANTI-CD30 ANTIBODY DRUG CONJUGATE THERAPY - The present disclosure, relates, in general to methods for improving adverse events in subjects having a mature T cell lymphoma and who are receiving treatment with an anti-CD30 antibody drug conjugate in combination with accompanying chemotherapy. Adverse events include peripheral neuropathy and neutropenia. | 2022-07-21 |
20220226440 | MODULATION OF CANCER IMMUNITY WITH TYPE 2 INNATE LYMPHOID CELLS, INTERLEUKIN 33, AND/OR INTERFERON INDUCED PROTEIN 44 - The present invention provides methods of modulating of cancer immunity using type 2 innate lymphoid cells (ILC2s), interleukin 33 (IL-33), IFI44 or combination thereof. Also provided are methods of preventing tumor metastasis and/or cancer progression by treatment with therapies comprising type 2 innate lymphoid cells (ILC2s), interleukin 33 (IL-33), IFI44 or combination thereof. Also provided are diagnostic methods for assessing cancer prognosis. | 2022-07-21 |
20220226441 | IMMUNE-CELL TARGETED BISPECIFIC CHIMERIC PROTEINS AND USES THEREOF - The present invention relates, in part, to targeted chimeric proteins with beneficial therapeutic effects, including, for example, effects mediated by chimeric proteins which comprise modified signaling agents two or more targeting moieties. Methods of treatment and pharmaceutical compositions comprising the chimeric proteins are also provided. The present invention finds use in the treatment of various disease and disorders. | 2022-07-21 |
20220226442 | INTERLEUKIN-2 AGENTS AND USES THEREOF - IL-2 agents that comprise IL-2 variants are disclosed as well as methods, compositions, and uses thereof. The IL-2 agents described herein can be used to treat and/or prevent various disorders and conditions. | 2022-07-21 |
20220226443 | COMPOSITIONS AND METHODS FOR TREATING RETINOPATHY - A pharmaceutical composition including insulin, Docosahexaenoic acid (DHA) and coenzyme Q10 and methods of manufacturing and using the composition are provided. | 2022-07-21 |
20220226444 | FORMULATIONS OF FOSAPREPITANT AND APREPITANT - This document relates to a composition comprising fosaprepitant, or a pharmaceutically acceptable salt thereof, and human serum albumin, wherein the fosaprepitant, or a pharmaceutically acceptable salt thereof, and the human serum albumin in the composition have a ratio by weight from about 1:0.1 to about 1:500. This document also relates to a composition comprising aprepitant and human serum albumin, wherein the aprepitant and the human serum albumin in the composition have a ratio by weight from about 1:80 to about 1:1000. This document also relates to a composition comprising fosaprepitant, or a pharmaceutically acceptable salt thereof, aprepitant and human serum albumin. | 2022-07-21 |
20220226445 | CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO - The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders. The present disclosure relates to a non-toxic mutant form of the | 2022-07-21 |
20220226446 | NEUROTOXIN COMPOSITIONS FOR USE IN IMPROVING LUNG FUNCTION - Disclosed herein are compositions and methods for use in reducing lung function inhibition. | 2022-07-21 |
20220226447 | ANTI-ABETA VACCINE THERAPY - A liposomal vaccine composition comprising: a. A β-amyloid (Aβ)-derived peptide antigen displayed on the surface of the liposome that comprises, consists essentially of or consists of amino acids 1-15 of Aβ, b. An adjuvant comprising monophosphoryl lipid A (MPLA) is used for inducing an anti-Aβ immune response in a human subject without inducing a serious adverse event. The β-amyloid (Aβ)-derived peptide antigen (SEQ ID NO: 1) is administered in an amount of 300-2000 μg, preferably around 1000 μg. The MPLA is administered in an amount of 15-600 μg, preferably around 175 μg. The liposomal vaccine composition is administered intramuscularly or subcutaneously. | 2022-07-21 |
20220226448 | ONE-STEP ARTIFICIAL ANTIGEN PRESENTING CELL-BASED VACCINES - Methods and compositions using artificial antigen presenting cells in immunotherapy. The artificial antigen presenting cells comprise substrate particles bound to endogenous MHC-peptide complexes obtained from one or more cells. Methods include administering the artificial antigen presenting cells to a patient to activate antigen-specific T cells. | 2022-07-21 |
20220226449 | IMMUNOGENIC COMPOSITIONS - The present invention provides an immunogenic composition comprising, consisting essentially of or consisting of: a) a cell expressing an interferon-β (IFN-β) receptor agonist, and b) a tumour antigen. The invention also provides methods of treatment using said compositions. | 2022-07-21 |
20220226450 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CLL AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2022-07-21 |
20220226451 | PEPTIDES AND T CELLS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2022-07-21 |
20220226452 | PEPTIDES AND T CELLS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2022-07-21 |
20220226453 | Alphavirus Antigen Vectors - Disclosed herein are alphavirus vectors that include neoantigen-encoding nucleic acid sequences derived from a tumor of a subject. Also disclosed are nucleotides, cells, and methods associated with the vectors including their use as vaccines. | 2022-07-21 |
20220226454 | ANTIGENIC COMPOSITION(S) AND METHOD(S) OF USE AGAINST PORPHYROMONAS GINGIVALIS FOR THE PREVENTION AND/OR TREATMENT OF INFECTION AND/OR DISEASES - Vaccines for | 2022-07-21 |
20220226455 | VACCINE AGAINST NECROTIC ENTERITIS IN POULTRY - An immunogenic polypeptide selected from an isolated | 2022-07-21 |
20220226456 | Attenuating bacterial virulence by attenuating bacterial folate transport - The invention relates to bacterial infections, vaccines directed against those infections and bacterial vaccines. More particularly, the invention relates to vaccines directed against | 2022-07-21 |
20220226457 | METHOD FOR THE EXPANSION OF HPV IMMUNOGEN SPECIFIC T-CELLS - The present invention provides a method for the expansion of HPV immunogen specific T cells, comprising the steps of: i. providing a phagocytosable particle comprising a core and a human papillomavirus (HPV) immunogen tightly associated to the core; wherein the HPV immunogen has an amino acid sequence that corresponds to the amino acid sequence of a HPV protein, or has an amino acid sequence that corresponds to an amino acid sequence of a part of a HPV protein; ii. providing APCs; iii. contacting the phagocytosable particle comprising a core and a HPV immunogen with the APCs from step ii in vitro, and under conditions allowing phagocytosis of the HPV immunogen by the APCs; iv. providing T-cells that have been harvested from a subject; v. contacting the T-cells with the APCs from step iii) in vitro, and under conditions allowing specific activation of HPV immunogen specific T-cells. The invention further provides an expanded population of therapeutically useful T-cells and their use in the treatment or prevention of cancer, particularly HPV positive cancers. | 2022-07-21 |
20220226458 | RECOMBINANT CHIMERIC BOVINE/HUMAN PARAINFLUENZA VIRUS 3 EXPRESSING RSV G AND ITS USE - Recombinant chimeric bovine/human parainfluenza virus 3 (rB/HPIV3) vectors expressing Respiratory Syncytial Virus (RSV) G protein or a recombinant RSV G protein, as well as methods of their use and manufacture, are provided. The rB/HPIV3 vector comprises a genome comprising a heterologous gene encoding the RSV G protein or the recombinant RSV G protein. Nucleic acid molecules comprising the sequence of the genome or antigenome of the disclosed rB/HPIV3 vectors are also provided. The disclosed rB/HPIV3 vectors can be used, for example, to induce an immune response to RSV and HPIV3 in a subject. | 2022-07-21 |